The lead asset in our Kv7 platform is BHV-7000 (formerly known as KB-3061). BHV-7000 is a potent activator of Kv7.2/Kv7.3, which are key subunits involved in neuronal signaling and in regulating the hyperexcitable state in focal epilepsy. We are also studying BHV-7000 for the treatment of KCNQ2 Developmental and Epileptic Encephalopathy (DEE) a rare, serious, and debilitating disease that manifests in infants and children as early-onset seizures and encephalopathy due to a defect in the function of the Kv7.2 channel caused by pathogenic mutations in the KCNQ2 gene. Furthermore, we have early-stage clinical studies underway focused on mood and pain disorders due to increasing evidence suggesting that Kv7.2/7.3 targeting drugs offer the potential to treat a spectrum of these neuropsychiatric diseases including, but not limited to, mood disorders such as major depressive disorder, bipolar disorder, and anxiety.